Cofactor Genomics Cements Clinical Diagnostic Plans as Immunotherapy Prediction Data Builds

Cofactor Genomics Cements Clinical Diagnostic Plans as Immunotherapy Prediction Data Builds

NEW YORK – Cofactor Genomics has expanded the exploration of potential clinical applications for its immune modeling technology, with new proof-of-concept data published this month from a study that used the firm’s predictive immune modeling technology, ImmunoPrism, to analyze a small cohort of high-grade serous ovarian cancer tumors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Source link

No Comments

Post a Comment